News Release

Cleanascite™ Cited In Study of Obesity-driven Oleoylcarnitine Accumulation in Tumor Microenvironment

MONMOUTH JUNCTION, NJ, March 6, 2025 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance product to study lipid accumulation models of disease in mice.

The citation is:

Chen, Chao, et al. "Obesity-driven oleoylcarnitine accumulation in tumor microenvironment promotes breast cancer metastasis-like phenotype." Acta Pharmaceutica Sinica B (2025).

Obesity is a significant risk factor for cancer and is associated with breast cancer metastasis. Nevertheless, the mechanism by which alterations in systemic metabolism affect tumor microenvironment (TME) and consequently influence tumor metastasis remains inadequately understood. Herein, we found that perturbations in circulating metabolites induced by obesity promote metastasis-like phenotypes in breast cancer. Oleoylcarnitine (OLCarn) concentrations were elevated in the serum of obese mice and humans. The article states “For the delipidation of mouse serum, Cleanascite Lipid Removal Reagent (BSG, USA) was employed following the manufacturer’s protocol designed specifically for serum samples. A 1:4 volume ratio of Cleanascite reagent to the sample was utilized.”. Notably, serum-deficient proteins and fats continued to induce EMT, highlighting the significance of small molecules (Supporting Information image shown here) .The study concludes that obesity-induced systemic environmental changes lead to the aberrant accumulation of OLCarn within the TME, making it a potential therapeutic target and biomarker for breast cancer.

“We now have over thirty references, validating Cleanascite™ use in helping to identify a lipid-based characteristic feature of in vitro cell response. Unlike alternative lipid-depletion methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. The essential requirement is the maintenance of cellular activity after lipid depletion, to determine whether lipid factors are associated with phenotypic changes in cultured cells” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords: Obesity, Breast cancer, Epithelial–mesenchymal transition, tumor microenvironment, Oleoylcarnitine, Cleanascite™, lipid depletion

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com